CareDx, Inc. (CDNA): Results of Operations and Financial Condition
CareDx, Inc. (CDNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cdna-20260730_earningsrele.htm EX-99.1 Document Exhibit 99.1 CareDx Announces Second Quarter 2026 Financial Results Second Quarter Revenue Growth of 52% to $132 Million Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66
How this was made
The 30-second read
Why it matters
The company’s Q2 performance and upward 2026 guidance provide a fresh valuation anchor for the stock, with non-GAAP profitability improving alongside testing services growth.
Market read
Upward guidance plus strong testing services growth is a direct catalyst for re-rating, while the GAAP gain from the divestiture is a key quality check for non-GAAP-focused investors.
What to watch
Guidance raises are meaningful, but traders should watch whether testing volume growth and reimbursement dynamics persist post-integration of Naveris and after Lab Products divestiture removes a revenue stream.
Background
CareDx is repositioning toward precision molecular diagnostics across transplant, specialty oncology, and cell therapy, including recent acquisition of Naveris and divestiture of Lab Products.
Ticker impact
CareDx reported Q2 2026 revenue up 52% to $132M and raised 2026 revenue guidance to $490M-$500M.
Likely positive near-term bias as guidance resets upward, though GAAP includes a one-time $113M gain from the Lab Products sale.
The filing discloses both the quarterly results and explicit upward guidance ranges, which typically drive repricing versus prior expectations. It also clarifies the Lab Products gain is excluded from non-GAAP, helping separate operating momentum from accounting effects.
Market effects
Supports sentiment for precision transplant diagnostics and molecular surveillance adoption, with evidence of reimbursement tailwinds (CMS coverage finalized).
Limited, primarily US-listed biotech/diagnostics sentiment.
Moderate, as transplant diagnostics demand and reimbursement dynamics can influence global payer and provider adoption narratives.
Counterpoint
The GAAP net income surge is heavily influenced by the $113M gain on the Lab Products sale, so operating cash generation and non-GAAP profitability matter more than headline earnings.
Key entities
- companyCareDx, Inc.
Reported Q2 2026 results and raised 2026 revenue and adjusted EBITDA guidance in an SEC 8-K.
- counterpartyEurobio Scientific
Buyer of CareDx’s Lab Products business, with the sale closing June 30 and generating a $113M GAAP gain.
- acquired_companyNaveris
Acquisition completed to strengthen CareDx’s diagnostics position; integration referenced in the release.
- regulatorCMS
Finalized Medicare coverage policy for AlloSure and AlloMap, supporting continued patient access.
